BACKGROUND An ideal medication for acid-related diseases would offer prompt stopping of blood flow as well as efficient symptom resolution. The aim of this study was to investigate the gastric acid suppression potency of a single oral dose of rabeprazole alone, compared with administration of rabeprazole plus mosapride. METHODS Twelve male volunteers, Helicobacter pylori (H. pylori)-negative,...

Lansoprazole is extensively metabolized by CYP2C19 and CYP3A4 in the liver, whereas rabeprazole is primarily converted non-enzymatically to rabeprazole-thioether, with only some being oxidized by CYP2C19 and CYP3A4. Lansoprazole and rabeprazole possess asymmetric sulfur in their chemical structure and have typically been used clinically as a racemic mixture. This article reviews the pharmacokin...

a simple and sensitive chemiluminescence-based method was established for the determination of rabeprazole.the proposed method was based on the enhancing effect of rabeprazole on ce(iv)-na2so3 -tb(iii) chemiluminescence reaction. a possible mechanism was discussed for chemiluminescence system by studying uv-vis, fluorescence and chemiluminescence spectra. the effects of various chemical paramet...

A simple and sensitive chemiluminescence-based method was established for the determination of rabeprazole.The proposed method was based on the enhancing effect of rabeprazole on Ce(IV)-Na2SO3 -Tb(III) chemiluminescence reaction. A possible mechanism was discussed for chemiluminescence system by studying UV-Vis, fluorescence and chemiluminescence spectra. The effects of va...

The aim of our study was to investigate the effects of rabeprazole, a proton pump inhibitor, on MDR1 expressed on human colon carcinoma cell line, Caco-2, and MDR1-overexpressing human cervical carcinoma cell line, HeLa cells selected by exposure to 100 nM vinblastine (Hvr100-6 cells). Inhibitory effects of rabeprazole on MDR1-mediated transport of Rhodamine123 were examined in these cells. A t...

A 24-week, double-blind, clinical trial of rabeprazole for the prevention of recurrent peptic ulcers caused by low-dose aspirin (LDA) has been reported, but trials for longer than 24 weeks have not been reported. The aim of this study is to assess the long-term efficacy and safety of rabeprazole for preventing peptic ulcer recurrence on LDA therapy. Eligible patients had a history of peptic ulc...

hour 23 (rabeprazole 100% vs. omeprazole 74%,. P < 0.02). Conclusions: Rabeprazole, 20 mg, demonstrated superior control of peptone mealstimulated . Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of. . new PPIs rabeprazole, pantoprazole and lansoprazole compared to omeprazole. Nov 1, 2007. Four studies of pantoprazole (Protonix) 40 mg versus omeprazole. Two studies of rab...

AIM To perform a systematic review of the efficacy of rabeprazole-based therapies in Helicobacter pylori eradication, and to conduct a meta-analysis comparing the efficacy of rabeprazole and other proton pump inhibitors when co-prescribed with antibiotics. METHODS Studies evaluating rabeprazole plus antibiotics were considered. Only randomized trials comparing rabeprazole and other proton pum...

Simple, sensitive high-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC) methods are developed for the quantitative estimation of rabeprazole and mosapride in their combined pharmaceutical dosage forms. In HPLC, rabeprazole and mosapride are chromatographed using 0.01M 6.5 pH ammonium acetate buffer-methanol-acetonitrile (40:20:40, v/v, pH 5.70+/-0.02) as the mobile p...

Rabeprazole sodium is a new stable pharmaceutical composition developed by us in tablet form, consisting of rabeprazole sodium as active ingredient, excipients, a separating layer and enteric coating. The manufacturing method involves pressing with preliminary wet granulation. In this work, a method was developed for the quantitative determination of rabeprazole sodium in tablets with simultane...